BioIVT Announces Expansive Fresh Leukopak Capability in Europe
WESTBURY, N.Y., Feb. 22, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it has increased its capacity to deliver readily-available fresh, standard and mobilized, human leukopaks. Building on decades of human derived cell collection expertise, this additional capability enables BioIVT to further scale its world-class network of diverse, highly characterized donors and makes the company a leading provider of fresh leukopaks in the UK and mainland Europe.
- WESTBURY, N.Y., Feb. 22, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it has increased its capacity to deliver readily-available fresh, standard and mobilized, human leukopaks.
- Building on decades of human derived cell collection expertise, this additional capability enables BioIVT to further scale its world-class network of diverse, highly characterized donors and makes the company a leading provider of fresh leukopaks in the UK and mainland Europe.
- To support this growing demand, BioIVT now has the ability to provide researchers across Europe with high quality, fresh starting material within 24 hours of collection.
- "Access to fresh leukopaks enables clients with the crucial elements needed for effective and efficient therapeutic development and approval," said Dr. Parijat Jain, Vice President, CGT at BioIVT.